Aptus Pharma Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹4(5.71%)
Premium (ELP)
Aptus Pharma Limited's successfully completed its Initial Public Offering and commenced trading on Sep 30, 2025 at the BSE exchange. The company raised 18,60,000 Shares through this public offering, comprising 18,60,000 Shares in fresh capital.
The IPO was priced within the band of ₹65 to ₹70, with minimum application lots of 2000 shares. The offering attracted significant investor interest during its subscription period from Sep 23, 2025 to Sep 25, 2025.
Share allotment was finalized on Sep 26, 2025, distributing equity to successful applicants. The stock's subsequent listing marked a significant milestone in the company's corporate history, providing public market liquidity to shareholders.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Aptus Pharma Ltd, incorporated in 2010, is engaged in the marketing and distribution of finished pharmaceutical formulations. The company manufactures and distributes a wide range of products across multiple therapeutic areas including antacids and PPIs, pain management, anti-inflammatories, antibiotics, cardiology and antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, and sachets. Its business divisions include Aptus Pharma, which focuses on acute therapies such as anti-infectives and pain management; Aptus CD Care, which specializes in chronic therapies; Aptus Wellcare, which offers wellness and nutraceutical products; and Aptus Global, which caters to the export market. As of March 31, 2025, the company had developed 194 pharmaceutical formulations across more than eleven therapeutic segments. It operates warehouses covering 15,732 sq. feet and 1,989 sq. feet in Ahmedabad, Gujarat. The company’s distribution network consists of 125 direct and sub-distributors supported by a sales team of 54 field personnel, and it employed 70 people as of March 31, 2025.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Diverse Product Range – Offers 194+ pharmaceutical formulations across 11+ therapeutic segments, catering to varied patient and healthcare requirements.
- Robust Distribution Network – Central warehouse in Ahmedabad and logistics partnerships enable safe, timely, and efficient delivery across target markets.
- High-Quality Compliance – Adheres to WHO-GMP protocols with rigorous testing at all production stages, ensuring consistent, safe, and credible products.
- Regulatory Compliance Risk – Inability to obtain, renew, or maintain required statutory and regulatory approvals could disrupt operations and affect financial performance.
- Customer Dependence Risk – Heavy reliance on a few key customers exposes revenue to potential declines if contracts are reduced or terminated.
- Intellectual Property Risk – Failure to protect intellectual property or facing infringement claims may lead to sales loss, liabilities, and negative financial impact.
- Tejash Maheshchandra Hathi
- Chatrabhuj Vallabhbhai Butani
- Kapilbhai Hasmukhbhai Chandarana
- Ghanshyam Vinubhai Pansuriya
- Milly Chetan Lalseta
- Riddhish Natwarlal Tanna
- Gaurang Rameshchandra Thakker
- Kripaliben Mayank Thakker
- Kunjal Piyushbhai Unadkat
Aptus Pharma Limited
Bigshare Services Private Limited